Policy and Practice of Inclusive Education put to the test in The N etherlands
MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic...
description
Transcript of MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic...
![Page 1: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/1.jpg)
MR CLEANMulticenter Randomized CLinical Trial of
Endovascular Treatment of Acute Ischemic Stroke in the Netherlands
C.B. Majoie, Y.B. Roos, A. van der Lugt, R. van Oostenbrugge, W. van Zwam, D.W. Dippel,
Depts of Radiology and Neurology, AMC Amsterdam, MUMC Maastricht and EMC Rotterdam,
The Netherlands
![Page 2: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/2.jpg)
MR CLEAN Trial
• Representative cases • Rationale • Purpose• Design• Trial organisation
www.mrclean-trial.org
![Page 3: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/3.jpg)
36-y-o W, aphasia, R arm paresis
![Page 4: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/4.jpg)
After stent retrieval: TICI 3
stent deployed
![Page 5: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/5.jpg)
Good outcome
6d FU MRI
![Page 6: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/6.jpg)
49 -Y-O M: L hemiparesis
Pre IAT Post IAT: TICI 3Complete recanalization
![Page 7: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/7.jpg)
Poor outcome
CT 8hrs postprocedure
![Page 8: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/8.jpg)
Rationale
• IAT increases likelihood of recanalization in patients with acute ischemic stroke,
BUT.....
• Overall effect on functional outcome of IAT as compared to no IAT is unknown at present
![Page 9: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/9.jpg)
Needed: a pragmatic clinical trial
• Intervention contrast should be closely matched to current evidence based practise (incl IVT 0-4.5 hrs)
• No restrictions in type of treatment unless strictly necessary
• Clinical inclusion criteria (stroke severity, time since onset) as broad as possible
![Page 10: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/10.jpg)
Purpose
• To assess the effect of IAT on functional outcome after acute ischemic stroke of ≤ 6 hour onset, in patients with a symptomatic proximal intracranial arterial occlusion
![Page 11: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/11.jpg)
Hypothesis• 10% absolute increase in the cumulative proportion of
patients with mRS 0-2 in the intervention group, compared to control group
![Page 12: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/12.jpg)
Design• Pragmatic phase III multicenter clinical trial
with blinded outcome assessment• Intervention contrast is IAT* versus no IAT
against a background of best medical management (incl IVT within 4.5 hrs)
*IA thrombolysis and/or mechanical thrombectomy at discretion of neurointerventionalist, treatment guidelines provided by executive committee
![Page 13: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/13.jpg)
Inclusion Criteria • A clinical diagnosis of acute stroke
– Deficit on NIHSS ≥ 2 (1,2) • CT (or MRI) scan ruling out intracranial hemorrhage • Proximal intracranial arterial occlusion on CTA
– distal ICA; M1,M2; A1, A2• The possibility to start treatment ≤ 6 hours from onset • Informed consent• Age ≥ 18 Y
1. Derex Cerebrovasc Dis 2002;2. Fisher Stroke 2006.
![Page 14: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/14.jpg)
Patient Subgroups• Patients
– not responding to IV thrombolysis– who can be treated within 6 hours, but do not
meet time window requirements for IVT– with contraindications for IV or IA thrombolytic
treatment (thrombectomy only)
![Page 15: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/15.jpg)
Yes
Yes
YesYes
No
No
Yes
Yes
Yes
Clinical diagnosis of ischemic stroke?
CT/MRI ruled out hemorrhage?
Relevant proximal intracranialanterior arterial circulation
occlusion on CTA/MRA/DSA?
Tx possible within6 hours?
CI for iv or ia alteplase?
Too late for ivtreatment
No/poorresponse to iv
alteplase
Endovascular treatment No endovascular treatment
CI for mechanical treatment?
Randomize
Yes
Contra-indications for iv/ia alteplase• Cerebral infarction within the previous 6 weeks.• History of intracerebral hemorrhage.• Severe head injury the previous 4 weeks.• Major surgery, gastrointestinal bleeding or urinary tract bleeding within 2 weeks.• Arterial blood pressure > 185/110 mmHg. • Blood glucose < 2.7 or > 22.2 mmol/L.• Clinical signs of hemorrhagic diathesis or platelet count <90 x 10*9/L, APTT>50 sec or INR >1.7.• Treatment with iv alteplase in a dose exceeding 0.9 mg/kg or 90 mg.
Contra-iondications for mechanical thrombectomy• Stenosis of the symptomatic carotid artery exceeding 70% (NASCET), which cannot be stented. • Blood glucose < 2.7 or > 22.2 mmol/l.• Arterial blood pressure > 185/110 mmHg.• INR >3.0 and/or platelet count <40 x 10*9/L
NIHSS ≥ 2?
![Page 16: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/16.jpg)
Design: outcomes • Primary
– mRS at 90 days • Secondary
– Imaging parameters• TICI (DSA)• Recanalization at 24 hours (CTA)• Infarct size at 5-7 days (CT)• Occurrence of major bleeding
– Clinical parameters• Mortality at 1 week and 90 days • NIHSS score at 24-48 hours and 1 week• ALD (Academic Linear Disability) scale, EQ5D and Barthel
index at 90 days
![Page 17: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/17.jpg)
Subgroup analyses
• Treatment modality– Urokinase or rtPA dose – Mechanical thrombectomy
• Pretreatment with iv rt-PA • Early vs late treatment • Stroke severity (NIHSS)
![Page 18: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/18.jpg)
Radiological Predictors of Improved Outcome
• CT/CTA Source: ASPECTS (Barber PA et al, Lancet 2000)
• CTA: Clot Burden Score (Puetz Int J Stroke 2008)
• CTA: Collateral score (Tan IYL, Ann Neurol 2007)
• CTP: Infarct size/Penumbra Index
![Page 19: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/19.jpg)
Center Eligibility
• Experience:– in acute stroke trials – with endovascular interventions– specific: with IA thrombolysis and mechanical
thrombecomy• at least 5 cases in the preceding year (treatment
and device-specific e.g. 5 cases treated with a retrievable stent)
![Page 20: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/20.jpg)
Planning and logistics
• 500 patients • 4 year inclusion period • 13 actively participating centers:
– 10 patients per year per center
![Page 21: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/21.jpg)
Conclusions
• MR CLEAN will provide insight into – Clinical and radiological predictors of good outcome– Clinical and radiological criteria that improve safety– Implementation strategies for best practises of
endovascular treatment – Data for cost-effectiveness analyses
www.mrclean-trial.org
![Page 22: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/22.jpg)
![Page 23: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/23.jpg)
Probability of finding a prox art occlusion according to day 0 NIHSS
(Derex L, Cerebrovasc Dis 2002)
![Page 24: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/24.jpg)
Low initial NIHSS score and proximal occlusion
• Acute stroke patients with a low NIHSS score on admission should not be excluded from early imaging.
• Indeed, stroke in the hyperacute stage is a dynamic process with a potential for neurologic deterioration, even in patients with an initial mild stroke severity.
• Some of these patients with mild symptoms on admission may actually suffer from a large vessel occlusion and the clinical course of their stroke remains open, depending on many factors such as severity of the perfusion deficit, the adequacy of collateral circulation and the presence or absence of early recanalization
Derex L Cerebrovasc Dis 2002;13:225-229
![Page 25: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/25.jpg)
![Page 26: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/26.jpg)
Statistical Analysis
• Effect of treatment estimated by means of ordinal logistic regression (shift analysis), which considers whole range of mRS
• Sliding dichotomy: definition of good outcome customized to each patient’s baseline condition
Murray GD et al. Design and analysis of phase III trials with ordered outcome scales:the concept of sliding dichotomy.J Neurotrauma 2005;22:511-17
![Page 27: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/27.jpg)
Ordered outcome scales: concept of sliding dichotomy
Murray et al (J Neurotrauma 2005)
• In stead of taking a single definition of “good outcome” for all patients (e.g.mRS ≤ 2), the definition is tailored to each patient’s baseline prognosis on entry of the trial.– For a patient with very severe injury survival alone might be
regarded as good outcome– For a patient with a mild injury, only full recovery would be
regarded as a good outcome
• Patients at the prognostic extremes have the potential to contribute to the estimation of treatment effect
![Page 28: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/28.jpg)
Sliding Dichotomy• Patients are grouped to a number of bands according to
baseline prognosis
• Each band has a customized dichotomy of the outcome scale to differentiate between “good” and “bad” outcome
• The total number of good outcomes in the intervention group will be compared with the corresponding number of outcomes in the intervention group
Murray et al (J Neurotrauma 2005)
![Page 29: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/29.jpg)
![Page 30: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/30.jpg)
RecanalizationGood outcome
![Page 31: MR CLEAN M ulticenter R andomized CL inical Trial of E ndovascular Treatment of A cute Ischemic Stroke in the N etherlands](https://reader036.fdocuments.us/reader036/viewer/2022062501/56816836550346895dddf4a8/html5/thumbnails/31.jpg)
RecanalizationGood outcome